Ananda Developments PLC Result of AGM
August 09 2024 - 4:56AM
RNS Regulatory News
RNS Number : 9295Z
Ananda Developments PLC
09 August 2024
ANANDA DEVELOPMENTS
PLC
("Ananda"
or the "Company")
Result of Annual General
Meeting
Ananda
Developments plc (AQSE: ANA) is pleased to announce that at the
Annual General Meeting of the Company held earlier today all
resolutions were duly passed by shareholders.
Proxy votes
received ahead of the meeting were as follows:
Resolution
Number
|
Resolution
Name
|
% of Votes
For
|
% of Votes
Against
|
Total Votes Cast (Excluding
Withheld)
|
Number of Votes
Withheld
|
|
|
|
|
|
|
01
|
To receive
and adopt the Annual Report and Financial Statements for the year
ended 31 January 2024
|
99.997%
|
0.003%
|
1,193,032,093
|
7,188
|
02
|
To re-elect
Charles Morgan as a director of the Company
|
99.997%
|
0.003%
|
1,193,017,758
|
21,523
|
03
|
To re-elect
Jeremy Sturgess-Smith as a director of the Company
|
99.997%
|
0.003%
|
1,193,017,758
|
21,523
|
04
|
To re-elect
Stuart Piccaver as a director of the Company
|
99.997%
|
0.003%
|
1,193,017,758
|
21,523
|
05
|
To re-elect
Clive Page as a director of the Company
|
99.997%
|
0.003%
|
1,193,017,758
|
21,523
|
06
|
To re-elect
Melissa Sturgess as a director of the Company
|
99.997%
|
0.003%
|
1,193,032,203
|
7,078
|
07
|
To re-elect
John Treacy as a director of the Company
|
99.997%
|
0.003%
|
1,193,017,758
|
21,523
|
08
|
To
re-appoint PKF Littlejohn as auditors to the Company
|
99.997%
|
0.003%
|
1,193,032,203
|
7,078
|
09
|
To approve
authority to allot of Securities of the Company
|
99.996%
|
0.004%
|
1,193,032,203
|
7,078
|
10
|
To disapply
Pre-emption Rights
|
99.812%
|
0.188%
|
1,193,032,203
|
7,078
|
To stay up
to date with the latest developments at Ananda, we encourage you to
follow and join our social media channels which
are:
· Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn:
https://www.linkedin.com/company/anadevelopments/
· Twitter:
https://twitter.com/AnandaPlc
· Investor Meet Company:
https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
The
Directors of the Company accept responsibility for the contents of
this announcement.
For more information please
contact:
InvestorHub
Engage with
us directly at Ananda Developments Investor Hub
|
Sign up
at https://investors.anandadevelopments.com/s/a66906
|
ANANDA DEVELOPMENTS
PLC
Chief Executive
Officer
Melissa
Sturgess
Finance Director
Jeremy
Sturgess-Smith
|
+44 (0)7463
686 497 ir@anandadevelopments.com
|
SP ANGEL CORPORATE FINANCE
LLP
Corporate
Finance
Richard
Morrison
Caroline
Rowe
|
+44 (0)20
3470 0470
|
Corporate
Broking
Abigail
Wayne
Rob
Rees
|
|
Yellow Jersey
PR
Charles
Goodwin
Soraya
Jackson
|
+44 (0)20
3004 9512
|
About Ananda
Developments
Ananda is
an AQSE-listed life sciences company focused on the research and
clinical development of CBD-based therapies for a range of complex
inflammatory pain conditions
For further
information on the Company visit https://anandadevelopments.com/
or sign up at https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/YeN3br
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NEXEANPNESSLEEA
Ananda Pharma (AQSE:ANA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Ananda Pharma (AQSE:ANA)
Historical Stock Chart
From Jan 2024 to Jan 2025